We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Primer Açık Açılı Glokom Olgularında Latanoprost-Timolol Maleat Sabit Kombinasyonunun Etkinliğinin Retrospektif Olarak Değerlendirilmesi.
- Authors
Çankaya, Ali Bülent; Elgın, Ufuk; Şımşek, Tülay; Batman, Aygen
- Abstract
Purpose: To investigate retrospectively the pressure-lowering effect of latanoprost-timolol maleate fixed combination (LTFC) in eyes with primary open-angle glaucoma (POAG). Materials and Methods: Five hundred and ninety-one eyes of 343 patients with POAG were included in our study. The eyes were receiving therapy of only LTFC and were divided into five groups according to the anti-glaucoma agents that had been used before LTFC treatment. Group 1 consisted of eyes in which none of the anti-glaucoma agents had previously been used. Group 2 consisted of eyes in which latanoprost had been used before LTFC treatment, Group 3 consisted of eyes in which timolol maleate had been uses, Group 4 consisted of eyes in which latanoprost and timolol maleate had been used, and finally Group 5 consisted of eyes in which timolol maleate-dorzolamid fixed combination (TDFC) had been used. The intraocular pressures (IOPs) before and after 3 months of LTFC treatment were compared. The alterations during LTFC therapy and resulting IOP changes were also recorded. Results: The mean IOP of the 591 eyes was 21.1±3.9 mmHg (13-34 mmHg) before LTFC therapy and 18.4±2.8 mmHg (12-29 mmHg) after 3 months of therapy (p<0.05). The mean decrease in IOP of the 105 eyes in Group 1 was 6.5±2.9 mmHg (24.8%±10.3), while it was 2.3±1.8 mmHg (10.7%±7.9) in the 222 eyes of Group 2, 3.8±2.2 mmHg (17.1%±9.7) in the 39 eyes of Group 3, and 0.7±1.1 mmHg (2.9%±5.6) in the 165 eyes of Group 4. Mean IOPs were not significantly different in the 60 eyes of Group 5 (p>0.05). The mean follow-up period was 11.6±4.4 months (3-18 months) after LTFC therapy. During the follow-up period, some changes in the treatment modalities were needed (such as the addition or change of medication or need for anti-glaucoma surgery) because of side effects of the medication in 17 eyes and the requirement of additional IOP reduction in 162 eyes. Conclusion: LTFC provides effective IOP control with low rates of side effects besides offering the advantages of fixed combinations of anti-glaucomatous agents.
- Subjects
TIMOLOL maleate; OPEN-angle glaucoma; EYE diseases; INTRAOCULAR pressure; OPHTHALMIC drugs; ADRENERGIC beta blockers
- Publication
Journal of Glaucoma-Cataract / Glokom-Katarakt, 2008, Vol 3, Issue 2, p77
- ISSN
1305-9173
- Publication type
Article